亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

恩帕吉菲 格列美脲 医学 二甲双胍 2型糖尿病 临床终点 内科学 磺酰脲 糖尿病 随机对照试验 内分泌学 胰岛素
作者
Martin Ridderstråle,Knut Robert Andersen,Cordula Zeller,Gabriel Kim,Hans J. Woerle,Uli C. Broedl
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier]
卷期号:2 (9): 691-700 被引量:325
标识
DOI:10.1016/s2213-8587(14)70120-2
摘要

Summary

Background

Metformin is the recommended first-line pharmacotherapy for patients with type 2 diabetes. There is no consensus on the optimum second-line pharmacotherapy. We compared the efficacy and safety of the sodium glucose cotransporter 2 inhibitor empagliflozin and the sulfonylurea glimepiride as add-on to metformin in patients with type 2 diabetes.

Methods

In this double-blind phase 3 trial, patients (aged ≥18 years) with type 2 diabetes and HbA1c concentrations of 7–10%, despite metformin treatment and diet and exercise counselling, were randomly assigned in a 1:1 ratio with a computer-generated random sequence, stratified by HbA1c, estimated glomerular filtration rate (eGFR), and region, to empagliflozin (25 mg once daily, orally) or glimepiride (1–4 mg once daily, orally) as add-on to metformin for 104 weeks. Patients and investigators were masked to treatment assignment. The primary endpoint was change from baseline in HbA1c levels at weeks 52 and 104. Differences in the primary endpoint were first tested for non-inferiority (based on a margin of 0·3%). If non-inferiority was shown, differences in the primary endpoint at week 104 were then tested for superiority. Analysis was done on the full-analysis set—ie, patients who were treated with at least one dose of study drug and had a baseline HbA1c value. This study is registered with ClinicalTrials.gov, number NCT01167881. A 104-week extension is ongoing.

Findings

Between August, 2010, and June, 2011, 1549 patients were randomly assigned to receive empagliflozin (n=769) or glimepiride (n=780); four patients in the empagliflozin group did not receive the assigned treatment. Empagliflozin was non-inferior to glimepiride at both timepoints. At week 104, adjusted mean difference in change from baseline in HbA1c with empagliflozin versus glimepiride was −0·11% (95% CI −0·19 to −0·02; p=0·0153 for superiority). Adverse events were reported in 661 (86%) patients treated with empagliflozin and 673 (86%) patients treated with glimepiride. Severe adverse events were reported in 72 (9%) patients in the empagliflozin group and 68 (9%) in the glimepiride group. Serious adverse events were reported in 119 (16%) patients in the empagliflozin group and 89 (11%) in the glimepiride group. Confirmed hypoglycaemic adverse events (plasma glucose ≤3·9 mmol/L or requiring assistance) at week 104 were reported in 19 (2%) patients treated with empagliflozin and 189 (24%) patients treated with glimepiride.

Interpretation

Empagliflozin might be an effective and a well tolerated second-line treatment option for patients with type 2 diabetes who have not achieved good glycaemic control on metformin.

Funding

Boehringer Ingelheim and Eli Lilly.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ava应助Kumquat采纳,获得10
12秒前
Sandy完成签到 ,获得积分10
1分钟前
可爱的函函应助周柏洋采纳,获得10
1分钟前
wang完成签到,获得积分10
1分钟前
1分钟前
Kumquat发布了新的文献求助10
1分钟前
wanci应助Kumquat采纳,获得10
1分钟前
2分钟前
周柏洋发布了新的文献求助10
2分钟前
mmyhn应助科研通管家采纳,获得10
2分钟前
隐形曼青应助wwwww采纳,获得10
3分钟前
3分钟前
ding应助小巧的雨柏采纳,获得10
3分钟前
紫熊发布了新的文献求助10
3分钟前
3分钟前
4分钟前
4分钟前
Ann完成签到,获得积分10
4分钟前
若眠完成签到 ,获得积分10
5分钟前
朴素的山蝶完成签到 ,获得积分10
5分钟前
andrele发布了新的文献求助10
5分钟前
6分钟前
上神发布了新的文献求助10
6分钟前
情怀应助韩宇航采纳,获得10
6分钟前
6分钟前
韩宇航发布了新的文献求助10
6分钟前
韩宇航完成签到,获得积分10
6分钟前
上神完成签到,获得积分10
6分钟前
77完成签到 ,获得积分10
8分钟前
黄黄完成签到,获得积分0
9分钟前
9分钟前
桐桐应助科研通管家采纳,获得10
10分钟前
wwwww发布了新的文献求助10
10分钟前
Xuxiaojun发布了新的文献求助10
10分钟前
紫熊完成签到,获得积分10
11分钟前
12分钟前
Haiverxin完成签到,获得积分10
12分钟前
Haiverxin发布了新的文献求助10
12分钟前
mmyhn应助科研通管家采纳,获得10
12分钟前
mmyhn应助科研通管家采纳,获得10
12分钟前
高分求助中
Sustainability in Tides Chemistry 1500
Handbook of the Mammals of the World – Volume 3: Primates 805
拟南芥模式识别受体参与调控抗病蛋白介导的ETI免疫反应的机制研究 550
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Manual of Sewer Condition Classification 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3068106
求助须知:如何正确求助?哪些是违规求助? 2722110
关于积分的说明 7476020
捐赠科研通 2369109
什么是DOI,文献DOI怎么找? 1256195
科研通“疑难数据库(出版商)”最低求助积分说明 609490
版权声明 596826